Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Epitope seeks bigger HIV diagnostics share in US:

This article was originally published in Clinica

Executive Summary

Epitope, a US maker of oral fluid diagnostics tests, has been attempting to broaden its domestic sales base by extending its marketing of its principal product, OraSure, into the military, community AIDS outreach and physician community. OraSure, which competes with blood and urine-based tests for HIV, is being developed by Beaverton, Oregon-based Epitope and its research partner, STC Technologies, for applications in drugs-of-abuse testing as well as hepatitis and syphilis.

You may also be interested in...



TTS Pharma Wants To Bring First Legal CBD Oil To The UK

TTS Pharma CEO Mark Tucker discusses his ambition to bring a legal CBD oil to the UK market, following the recent submission of a European Union novel food application.

Italy Round-Up: Mylan And Polifarma Strike Deal, OTC Market Stable, Cholesterol-Lowering Probiotic Launch

The latest news from Italy's OTC and supplements markets, including the latest sales figures, business deals, product launches, ad regulation and local association activities.

Sandoz Pledges Price Stability Amid Coronavirus

Sandoz CEO Richard Saynor has pledged that the company will ensure stable pricing for essential coronavirus-related medicines amid concerns over how the outbreak will affect the supply chain.

Topics

UsernamePublicRestriction

Register

MT083276

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel